Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients.

Psychiatry research - 30 Jan 2010

Houston John P, Fijal Bonnie, Heinloth Alexandra N, Adams David H

Abstract excerpt

In patients from two clinical trials, we investigated the associations of single nucleotide polymorphisms (SNPs) in candidate genes with prolactin level changes during treatment with olanzapine/fluoxetine combination. In both cohorts, three dopamine receptor D2 (DRD2) SNPs were associated with prolactin changes. DRD2 may influence susceptibility to hyperprolactinemia associated with antipsychotic treatment.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Benzodiazepines
Share to Depression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug Combinations

Share to Fluoxetine

Share to Prolactin

Share to Receptors, Dopamine D2

Source

Identifiers

PMID: 19896213
DOI: 10.1016/j.psychres.2009.06.014

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients.PMID 19896213Read ↗

Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.Semantic proximity Read ↗

Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.Semantic proximity Read ↗

The pharmacogenetics of treatment with olanzapineSemantic proximity Read ↗

Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in healthy volunteers. Association with pharmacogeneticsSemantic proximity Read ↗

Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.Semantic proximity Read ↗

Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.Semantic proximity Read ↗

Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia.Semantic proximity Read ↗

Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysis.Semantic proximity Read ↗

UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder.Semantic proximity Read ↗

The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis.Semantic proximity Read ↗

Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.Semantic proximity Read ↗

DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.